Abstract | Standard protocols for the diagnosis of neoplasms in the gastrointestinal tract are based on histopathologic analysis in combination with clinical information. With the completion of the Human Genome Project in 2003, our understanding of the contribution of genetics to human disease has increased exponentially. This knowledge is gradually being incorporated into clinical decision-making. However, the rate at which molecular biomarkers are validated for use in mainstream clinical applications has lagged far behind that of biomarker discovery. Nevertheless, a number of molecular biomarkers are available for use in the diagnosis and management of gastrointestinal tract neoplasms. This article reviews the most common molecular biomarkers currently available for neoplasms of the luminal gastrointestinal tract and pancreas. In neoplasms of the esophagus, for which no biomarkers are currently used in routine clinical practice, those that have shown the most promise in early clinical validation studies are discussed.
Introduction
The completion of the Human Genome Project in 2003 accelerated the pace of discovery of genes involved in the genesis of human disease. From these discoveries, the concepts of 'genomic medicine' and 'personalized medi cine' emerged, in which the results of genetic tests are used to direct the clinical management of patients with various diseases. 1 Genetic markers are most readily being used in the diagnosis and therapy of human tumors, includ ing those of the gastrointestinal tract. Standard proto cols for the diagnosis of neoplasms in the gastro intestinal tract involve the identification of dysplasia and/or cancer. Although the histopathological diagnosis of cancer of the gastrointestinal tract is usually unambigu ous, there are a number of limitations with this approach, including biopsy sampling error, interobserver variability and difficulty in obtaining adequate biopsy specimens from a number of gastrointestinal organs. 2 Thus, in the era of personalized medicine, molecular profiling and the use of biomarkers has become a rapidly expand ing field with a central role not only in the diagnosis of neo plasia, but also in the selection of individualized anticancer therapies. 3 The Biomarker Definitions Working Group of the NIH defines a biomarker as "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention". 4 Clinically, biomarkers can either be used for diagnosis (to identify patients with a disease or abnormal condi tion) or to predict prognosis, progression (including the staging and extent of disease) and response to a therapeutic intervention. 4 In general, molecular bio markers used in the diagnosis or treatment of cancer fall into several broad categories, each of which indicate the presence of biologic properties unique to malignant cells. These properties include cell division indepen dent of exogenous mitogenic stimulation, resistance to growthinhibitory signals, avoidance of apoptosis, limitless replica tion, development of adequate vascular supplies, the capacity to invade and metastasize, and the establishment of an inflammatory microenvironment. 5, 6 This article reviews the most common clinically avail able molecular biomarkers for neoplasms of the stomach, pancreas and colon, and the biomarkers that have shown the most promise in clinical validation studies for cancers of the esophagus.
Cancers of the esophagus
Esophageal cancers are among the most deadly of gastro intestinal malignancies, with 5year mortality rates exceeding 87%. 7 Squamous cell carcinoma and adeno carcinoma are the two major histologic types. Worldwide, >90% of esophageal cancers are squamous cell carcino mas; however, in the US the incidence of the latter has declined in parallel with a dramatic rise in the incidence of adenocarcinoma. 8 Survival for both esophageal tumor types can be improved if they are detected in the early stages. 9, 10 Currently, no biomarkers for either histologic type of esophageal cancer are in widespread clinical use; however, those that have shown the most promise in early clinical validation studies are discussed below. cell carcinoma. 11 Unfortunately, the sensitivity of this technique for detecting squamous dysplasia or early cancer is only ~50%. 12 To improve these detection rates, a DNAmethylationbased biomarker panel has been used to assess specimens collected by esophageal balloon cytology. DNA methylation is an epigenetic mechanism whereby cells can turn off gene expression by the addi tion of methyl groups to nucleotides in the promoter regions of genes. However, even when the 'best' DNA methylationbased biomarker panel was used, the sensi tivity was still only 50% for the detection of squamous cell dysplasia. 12 Additional studies of molecular biomarkers for early detection of esophageal squamous carcinoma are clearly warranted.
Esophageal adenocarcinoma
The majority of esophageal adenocarcinomas are thought to arise from the metaplastic epithelium of Barrett esopha gus; 13 thus, molecular biomarkers capable of identi fying patients who have the highest risk of cancer progression have been the primary focus of research efforts in this setting (Table 1) . very little work has been done to uncover molecular biomarkers that are diag nostic of Barrett esophagus itself. 16, 17 Among the more promising biomarkers predictive of disease progression in patients with Barrett esophagus is aneuploidy (an abnormal number of chromosomes) and/or increased levels of tetraploidy (that is, in >6% of cells within a tissue). Normal (diploid) cells contain two copies of each chromosome, which increase to four copies (tetraploid) just before cell division. Aneuploidy and/or increased tetraploidy, which can be detected by flow cytometry, might be better predictors of neo plastic progression in patients with Barrett esophagus than a histologic diagnosis of no dysplasia, indefinite, or lowgrade dysplasia. 18, 19 loss of heterozygosity (loH) refers to the loss of a section of a chromosome that contains one of the two alleles for a gene. The tumorsuppressor gene TP53 (which encodes p53) is located on the small (p) arm of chromosome 17, and 17ploH (which is a promis ing biomarker of cancer progression in patients with Barrett esophagus) is thought to involve loss of a TP53 allele. In one study, 17ploH in biopsy specimens from patients with Barrett esophagus was associated with a 3year cumulative incidence of cancer of 38%, regard less of the presence or absence of dysplasia. 20 By con trast, biopsy specimens that retained both alleles of 17p were associ ated with a cumulative incidence of cancer at 3 years of 3.3%. 20 Although these results are promising, the use of flow cytometry to detect 17ploH is techni cally diffi cult and is currently available only in highly specialized research laboratories. Alternative techniques to detect 17ploH, such as automated imaging cyto metry and fluorescence in situ hybridization, are more feasible for routine clinical practice and are currently being explored. 21, 22 The complexity of human tumorigenesis makes it unlikely that a single molecular biomarker will be adequate to predict cancer development. Studies have, 23 The finding of all three molecular abnormalities predicted an 80% risk of cancer at 6 years whereas biopsy specimens that did not demonstrate any of these abnormalities had an incidence of cancer of 12% at 10 years. 23 The use of a sixgene biomarker panel to assess DNA methylation status in biopsy samples of metaplastic Barrett epithelium, in combination with the patient's age and the length of the Barrett esophageal segment, has been used to generate a predictive model of neoplastic progression. 24 
Cancers of the stomach

Gastric adenocarcinoma
The two major histological variants of adenocarcinoma of the stomach are termed diffusetype and intestinal type tumors. In general, individuals with diffusetype tumors typically have a worse prognosis than those with intestinaltype tumors. ERBB2 encodes a member of the epidermal growth factor receptor (EGFr) family of receptor tyrosine kinases. Amplification of the ERBB2 gene and/or overexpression of HEr2, its protein product, have been identified in esophageal adenocarcinoma as well as in breast, ovarian and gastric cancers, among others. 25, 26 HEr2 overexpression is more common in intestinaltype (21.5%) than in diffusetype (2%) gastric adenocarcinoma. 26 HEr2 expression levels in gastric adenocarcinomas has been proposed as a potential biomarker to predict prognosis and response to therapy. HEr2positive gastric cancers were initially thought to have a poor prognosis; however emerging data suggest that HEr2 expression levels might have no prognostic relevance in patients with gastric cancer. 26, 27 However, HEr2 expression might still be useful as a bio marker to predict therapeutic response; trastuzumab, an antiHEr2 monoclonal antibody, administered in addition to standard chemotherapeutic agents showed a benefit in patients with HEr2positive gastric cancers ( Table 1) . 28 Immunohistochemistry and fluorescence in situ hybridiza tion are the methodologies currently most often used to assess HEr2 status. 25, [29] [30] [31] The current model for development of intestinaltype gastric adenocarcinoma involves a stepwise progression REviEwS from nonatrophic gastritis through multifocal atrophic gastritis, intestinal metaplasia, dysplasia and finally adeno carcinoma. 32 In populations at a high risk of developing intestinaltype gastric adenocarcinomasuch as Japanese individuals-serum pepsinogen levels are a useful biomarker for the diagnosis of severe gastric atrophy with or without intestinal metaplasia (Table 1) . Patients with extensive atrophy are at high risk of neo plastic progression. 33 Pepsinogens I (PGI) and II (PGII) are produced by chief cells and mucous neck cells in the oxyntic mucosa. Whereas PGI is produced exclusively by these cells, PGII is also produced by cells in the pyloric glands and Brunner glands. 32 Thus, in patients with atrophy of the gastric corpus, loss of the PGIproducing cell mass leads to a marked decrease in levels of PGI and a low serum PGI:PGII ratio (levels of the latter are unaffected because PGII is still produced by cells in the pyloric and Brunner glands). 32 In several studies conducted in Japanese and some European popula tions, serum PGI levels <70 ng/l and a PGI:PGII ratio <3.0 had a high sensitivity (~70%) and very high speci ficity (~97%) for the detection of atrophy in the gastric corpus. 34 Patients with an abnormal serum PGI:PGII can be referred for endoscopic evaluation.
hereditary diffuse gastric cancer most gastric cancers are sporadic, but familial cluster ing is observed in ~10% of cases. 35 Hereditary diffuse gastric cancer (HDGC) is characterized by an autosomal dominant susceptibility to diffusetype gastric adeno carcinoma, which accounts for ~1-3% of the familial cases. 35 The majority of patients with HDGC carry muta tions in the tumorsuppressor gene CDH1, which encodes cadherin 1 (also known as Ecadherin). CDH1 mutations have been described in patients with diffuse type, but not intestinaltype, gastric cancers (Table 1) . [36] [37] [38] In 2004, revised criteria for considering CDH1 genetic testing in patients with suspected HDGC were proposed (Box 1). These criteria are applicable to individuals with gastric cancer in North America and other regions where gastric cancer has a low incidence; however, they may not be appropriate for use in highincidence regions such as Japan and Korea. 39 molecular testing for CDH1 mutations (that is, sequencing of the coding region of CDH1 or analysis of deletions and duplica tions) has a detection rate of about 30% in patients who meet the clinical criteria for a diagnosis of HDGC in the absence of a known familial diseasecausing mutation. Given that current data suggest that a prophylactic total gas trectomy should be considered in asymptomatic car riers of CDH1 mutations, such testing should only be performed with the support of appropriate genetic and clinical counseling. 40 Gastrointestinal stromal tumor Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastro intestinal tract. Although GISTs occur most often in the stomach, they can be found elsewhere in the luminal gut and excep tionally also outside the digestive system. These tumors originate in interstitial cells of Cajal, which regulate peristalsis in the digestive tract. most GISTs are sporadic and arise because of a somatic gainoffunction mutation in the KIT gene, which encodes mast and stem cell growth factor receptor (also termed Kit or CD117). 42 Such mutations result in ligandindependent tyrosine kinase activity. mutations in the PDGFRA gene (which encodes the αtype plate letderived growth factor receptor [PDGFrα]) seem to be mutually exclusive of KIT mutations and have been identified in 3-5% of GISTs. 43 Imatinib, a tyrosine kinase inhibitor used in the treatment of patients with Philadelphiachromosomepositive chronic myelo genous leukemia, targets both the Kit and PDGFrα kinases and is also beneficial in the treatment of patients with GISTs. 44 Patients with localized GISTs in whom surgical resec tion is complete do not require further medical treat ment. However, patients with unresectable tumors, advanced, metastatic or recurrent disease might be candidates for imatinib treatment. Adjuvant imatinib therapy might also increase recurrencefree survival after resection of the primary GIST. 45 Since most patients with GISTs respond to targeted therapy with imatinib, differ entiation of GISTs from other tumors considered in the differential diagnosis is essential. Kit is expressed in 95% of GISTs, and expression of this protein is, therefore, a major diagnostic criterion for these tumors. 46 Another diagnostic marker now used in some laboratories is expression of anoctamin 1 (encoded by ANO1), which can be detected by immunohistochemistry (Table 1) . 47, 48 In addition, mutations in the KIT and PDGFRA genes can be used as biomarkers for predicting a therapeutic response to imatinib therapy. KIT mutations can also be used to predict overall prognosis (Table 1) . For example, patients with GISTs that show KIT exon 11 mutations have a significantly higher partial response rate to imat inib (83.5%) than do those with KIT exon 9 mutations (47.8%; P = 0.0006), or those with wildtype KIT or wild type PDGFRA (0.0%; P <0.0001). 49 Furthermore, patients whose GISTs harbored KIT exon 11 mutations also had a longer eventfree survival (687 days) and overall survival, with a reduction in the risk of death of 95%, than did those whose tumors contained KIT exon 9 mutations, wildtype KIT or wildtype PDGFRA. 49 Additionally, among imatinibtreated patients, those with exon 9 muta tions in KIT had a relative risk of disease progression of 1.71 and a relative risk of death of 1.90 versus those with exon 11 KIT mutations. 50 In patients with exon 9 KIT mutations, improved progressionfree survival could be achieved with a higher dose of imatinib (800 mg daily versus 400 mg daily). 50 Despite the initial favorable response of most GISTs to imatinib, data suggest that the tumors eventually become resistant to this agent owing to the acquisition of sec ondary mutations within the KIT gene. 51 Additional agents that target the Kit and PDGFrα kinases are cur rently under investigation. 52 However, as mutations in the KIT gene are biomarkers of therapeutic response to imatinib, mutation analyses should be pursued regardless of whether or not the tumor expresses Kit (CD117) on immunohistochemistry. Several clinical and research laboratories offer mutational analyses for KIT and PDGFRA. 53 Cancers of the pancreas pancreatic adenocarcinoma Pancreatic adenocarcinomas originate from the ductal epithelium and progress from minimal dysplasia (pan creatic intraepithelial neoplasia [PIN] grades 1A and 1B) to severe dysplasia (PIN grades 2 and 3) before becoming invasive. 54 No biomarkers are currently recommended in routine screening for pancreatic cancer. By contrast, CA199 (carbohydrate antigen 199 or sialylated lewis [a] antigen) is a clinically useful biomarker for moni toring therapeutic response and for the early detec tion of recurrent disease after treatment (Table 1) . [55] [56] [57] [58] However, CA199 has some limitations as a marker for pancreatic cancer, including a lack of specificity owing to the fact that other conditions such as biliary cholestasis can also elevate levels of this protein. 54 Although most cases of pancreatic cancer are sporadic, familial cluster ing is observed in ~5-10% of cases, and in 10-20% of such cases a hereditary component might be involved. 59 Heritable conditions, such as hereditary pancreatitis, cystic fibrosis and Peutz-Jeghers syndrome, can increase an individual's risk of developing pancreatic cancer, and specific genetic tests are available to identify caus ative mutations for most of these diseases. 59 However, no consensus clinical recommendations are available at this time for pancreatic cancer screening in these highrisk individuals. 59 pancreatic cystic neoplasms mucinous cystadenomas and intraductal papillary muci nous neoplasia are types of pancreatic cystic neoplasms that carry a risk of progression to malignancy. owing to this increased risk, surgical resection of these lesions should be considered. 60, 61 By contrast, patients with small, benign, serous cystadenomas can be managed conservatively. 62, 63 Distinguishing premalignant muci nous cysts from benign nonmucinous cystic lesions is, 63 However, EUS does enable aspiration of the cyst fluid, which can then potentially be subjected to several types of analy ses. one consideration in ordering tests on aspirated cyst fluid is the volume of the sample. Since histopathology is an essential tool in the diagnosis and classification of mucinous pancreatic cysts, aspirate fluid cytology should be prioritized. 64 Any remaining specimen can be considered for ancillary investigations (measurement of carcino embryonic antigen [CEA] levels and molecular diagnostic tests).
measurement of CEA levels in aspirated fluid samples is currently the most accurate diagnostic biomarker to distinguish nonmucinous from mucinous pancreatic cysts (Table 1) ; 61, 63 however, CEA levels cannot dis criminate between benign and malignant mucinous cysts. 61, 63 Data published by the massachusetts General Hospital laboratory suggest that a cyst fluid CEA level of <192 ng/ml is indicative of a nonmucinous cyst whereas CEA levels >192-200 ng/ml are suggestive of a mucinous cyst. 63 However, these cutoff values might not be appropriate for use in other laboratories, as tech niques for hand ling and processing of cyst fluid samples intended for CEA measurements are not standardized. 63 Commercial assays for measuring CEA have not yet been validated for use in assessing cyst fluid. 63 In addition, measurement of CEA levels in cyst fluid is not approved by the FDA as either a screening or diagnostic test for pancreatic cancer. 63 molecular testing of cyst fluid has increased in recent years owing to the commercial availability of assays and the ability to carry out such tests on extremely small amounts (200 μl) of cyst fluid (Table 1) . 63 In the Pancreatic Cyst DNA Analysis (PANDA) study, Khalid et 65 The molecular analy sis consisted of identi fying a point mutation in the first exon of the KRAS gene, loH in a panel of 15 tumor suppressor genes, and determining DNA quantity and quantity. The presence of a KRAS mutation in exon 1 had the highest speci ficity (96%) for detecting muci nous cysts in this cohort; however, sensitivity was low (45%). An allelic loss amplitude >80%, determined by calculating the proportion of cellular DNA demon strating loH, 65 was the most accurate test for detection of malignant cysts.
Shen et al. compared the diagnostic results achieved using the PathFinderTG ® test to those of a clinical con sensus diagnosis in patients with pancreatic cysts. 66 The clinical consensus diagnosis classified pancreatic cysts as malignant, benign mucinous or benign non mucinous using histology or a combination of two of the follow ing three characteristics: EUS findings, CEA levels in the cyst fluid, or cytologic findings. The consensus clinical diagnosis accorded with the molecular diag nosis in five of six (83%) malignant cysts, 13 of 15 (87%) benign mucinous cysts and 13 of 14 (93%) benign non mucinous cysts. However, molecular diagnosis resulted in one false negative diagnosis of a malignant cyst, two benign mucinous cysts being classified as benign nonmucinous, and one nonmucinous cyst being classified as a benign mucinous cyst. 66 Although these data are promising with regard to the use of molecular diagnostic tests to dis tinguish nonmucinous from mucinous cysts and malig nant from benign cysts, large, prospective, randomized, controlled, clinical trials are still needed to determine the clinical utility of molecular testing of pancreatic cyst fluid.
Cancers of the colon
Sporadic colorectal cancer Worldwide, colorectal cancer incidence and mortality rates are on the rise; however, they have declined in the USA, perhaps because of advances in colorectal cancer screening. 67, 68 In the past 10 years, stool DNA tests have been the most intensively studied molecular approach to colorectal cancer screening. 69 Several studies have compared the rates of detection of advanced adenomas and invasive tumors achieved by stool guaiac testing and stool DNA testing, respectively. one study compared fecal occult blood testing using the Hemoccult ® and HemoccultSensa ® assays (both from Beckman Coulter Inc., Fullerton, CA), a stool DNA test with a 23marker panel (SDT1) and another stool DNA test that used only three targeted markers (SDT2) with colonoscopy, which is the goldstandard technique for detection of adenomas and colorectal cancer. 70 overall, rates of detection of colorectal neoplasia did not differ between the HemoccultSensa ® and the SDT1 tests; however, detection rates for SDT1 were significantly greater than those for Hemoccult ® (P = 0.02). 70 Furthermore, detec tion rates for colorectal neoplasia were considerably better with SDT2 than with either of the fecal occult blood detection assays. 70 moreover, SDT2 had signifi cantly higher rates of detection for advanced adenomas >1 cm (46%) compared with either Hemoccult ® (10%; P <0.001) or HemoccultSensa ® (17%; P<0.001). 70 one drawback of the SDT2 assay, however, was a higher falsepositive rate (16%)-that is, normal colonoscopy findings in patients with a positive test result-than either the Hemoccult ® (4%) or HemoccultSensa ® (5%) assays. 70 Stool DNA testing as a screening modality (Table 1) has been endorsed by the American Cancer Society, the US multisociety Task Force, the American College of radiology and the American College of Gastroenterology, but not yet by the US Preventive Services Task Force. 71, 72 Clinical and pathologic staging are currently the gold standard methods of predicting the prognosis of patients with colorectal cancer, but these conventional techniques do not address whether and how patients will respond to chemotherapy. In the past 5 years KRAS has become a biomarker of interest with respect to predicting the response to antiEGFr therapies (Table 1) . Cetuximab and panitumumab are antiEGFr monoclonal anti bodies that have been approved by the FDA for treatment of patients with metastatic colorectal cancer. 73 Although EGFr is expressed in approximately 85% of metastatic colorectal cancers, only a proportion of patients with such tumors demonstrate a clinical benefit from anti EGFr treatment. 74 mutations of KRAS that activate signaling confer resistance to antiEGFr monoclonal antibody therapies. 74 In fact, the National Comprehensive Cancer Network and American Society of Clinical oncology guidelines recommend that all metastatic colorectal tumors should be tested for KRAS mutations before beginning antiEGFr monoclonal antibody therapy and that only in those patients whose tumors contain wildtype KRAS should therapy be initiated. [74] [75] [76] In general, mutations in KRAS are found in 30-40% of colorectal cancers. 74 KRAS mutation testing is most commonly performed on DNA extracted from formalinfixed, paraffin embedded tumor samples. 74 Factors that can affect the results of KRAS testing include the purity and quantity of tumor cells and the fixation and processing of the tissues; therefore, pathologist expertise is essential. A variety of techniques can be used for KRAS mutation analysis, including realtime PCr, Sanger sequencing and pyrosequencing. 77 Familial adenomatous polyposis Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome of predisposition to colon cancer. Patients with FAP develop hundreds to thousands of adenomatous colonic polyps, which invariably lead to colon cancer if untreated. The clinical diagnosis of FAP is made when a patient has ≥100 colorectal adenomas (disease onset usually occurs in adolescence or early adulthood). 78 A milder form of the disease (attenuated FAP) is characterized by <100 colon adenomatous polyps and a later onset (occurs between 35-45 years of age). 79 FAP is most commonly caused by nonsense or frameshift mutations in the APC tumorsuppressor gene, which lead to premature truncation and loss of function of the APC protein. Full gene sequencing is currently the gold stan dard for detecting APC mutations (Table 1) . 80 In addi tion, deletion and/or duplication analysis and protein truncation assays are also clinically available. 84 Faulty DNA mismatch repair leads to the accumulation of genetic mutations, which can ultimately result in malignant transformation of cells. Germline mutations in MLH1 and MSH2 account for the vast majority (~90%) of initiating mutations in families affected by HNPCC. mutations in other DNA mismatch repair genes are less common; those in MSH6 account for ~7-10% and in PMS2 <5% of mutations in families with HNPCC. 85 microsatellites (small repetitive sequences of nucleo tides located throughout the genome) are particularly prone to acquiring mutations when DNA mismatch repair is defective. A validated panel of five such loci is used to determine whether a tumor demonstrates abnormal lengthening or shortening of the nucleotide repeats in these loci, which is termed microsatellite instability (mSI). 86 Tumors with DNA abnormalities in two or more of these microsatellite loci are classified as mSIhigh (mSIH). 84 Since only a fraction of individuals who meet the clinical criteria in the revised Bethesda guidelines (developed to aid in the identification of individuals with HNPCC who should be tested for mSI) will in fact have HNPCC, germ line mutation testing has a diagnostic yield of <50%. 84 Thus, in patients who meet these criteria, tumor samples should initially be tested for mSI, which adds to the predictive ability of the clinical criteria. only patients whose tumors are mSIH should undergo genetic testing (Table 1) , 84 consisting of mutation scanning and a full sequence analysis of the DNA mismatch repair genes (Table 1 ). Deletion and/or duplication analy sis is used to identify large deletions or gene rearrangements that cannot be detected by sequencing. Another mechanism of loss of MLH1 function is promoter methyla tion, 84, 87 which can be identified by methylationspecific PCr. However, HNPCC is not the only setting in which mSI can be identified. For example, 10-20% of sporadic colorectal adenocarcinomas demonstrate mSI owing to MLH1 promoter methylation or acquired somatic mutations in mismatch repair genes. 87 Although mSIH is quite a sensitive marker for diag nosis of HNPCC, a small proportion of patients with mutations in DNA mismatch repair genes will not be identified by mSI testing. Immunohistochemistry to detect the expression of hmSH2, hmSH6, mlh1 and PmS2 proteins can, therefore, be performed to supple ment mSI testing. 84 However, some gene mutations result in the loss of gene function but not in the loss of the entire protein product, which can manifest as a false positive immunostain (that is, the protein is detected by immunohistochemistry but it is not functionally active). 88 Thus, from a practical standpoint, immuno histochemistry might be the preferred option for the first round of testing because it is more widely available than molecular testing for mSI. regardless of whether immunohistochemistry or mSI testing is done initially, DNA sequence analysis remains the gold standard for confirming a mutation in a mismatch repair gene. once a specific mutation has been identified in an affected family, targeted molecular analysis can be carried out in relatives, saving both time and costs. As noted above for patients with suspected FAP, the involvement of a genetic counselor before conducting genetic testing for HNPCC is also advised. 84 Patients with stage II or stage III HNPCC, or with spor adic colorectal tumors that demonstrate MLH1 silencing by promoter methylation, derive either no benefit or have a two to threefold increase in mortal ity when treated with adjuvant chemotherapy based on 5fluorouracil (Table 1) . [89] [90] [91] [92] [93] [94] Such regimens should not, therefore, be offered to these patients.
Conclusions
Completion of the Human Genome Project has ushered in an era of personalized medicine. Advances in under standing how specific genes are involved in human diseases have led to improvements in diagnosis and management. As a result of this wave of biomedical discovery, a number of molecular biomarkers are now available for clinical use that can aid in diagnosis and therapeutic decisionmaking for gastrointestinal cancers. In addition, multiple online tools can provide assistance with questions or decisions on molecular testing. 53, 95 The GeneTests website is a publicly funded medical genetics information resource developed for physicians, other healthcare providers and researchers. 95 This site also houses diseasespecific reviews written by international experts who discuss the role of genetic testing and its application to the management of inherited genetic dis orders, as well as a national and international directory of genetic testing laboratories, genetic counseling clinics and prenatal diagnosis clinics. 95 The efforts devoted to genomic discoveries have changed our understanding of disease pathogenesis over the past few years and we anticipate that such knowl edge will translate into further applications for mol ecular pathology in the management of diseases of the gastrointestinal tract.
Review criteria
The MeDLINe and PubMed databases were searched for english-language abstracts and full-text articles published between 1996 and May 2010. To locate articles, the terms "biomarker" and "molecular" were each searched in concert with the organs of interest: "esophagus", "gastric", "stomach", "pancreas", "pancreatic cyst" and "colon". Reference lists were checked for additional relevant papers. Other references were located during searches of the GeneTests (http://www.ncbi.nlm.nih. gov/sites/GeneTests/?db=GeneTests) and OMIM (Online Mendelian Inheritance in Man; http://www.ncbi.nlm.nih. gov/omim) websites.
